Inactive Instrument

Tauriga Sciences, Inc. Stock price Other OTC

Equities

TAUG

US87669X2053

Pharmaceuticals

Sales 2020 0.23 Sales 2021 0.29 Capitalization 29.3M
Net income 2020 -3M Net income 2021 -3M EV / Sales 2020 15,901,203 x
Net Debt 2020 373K Net cash position 2021 1.04M EV / Sales 2021 99,058,952 x
P/E ratio 2020
-0.87 x
P/E ratio 2021
-6.09 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order CI
Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Tauriga Sciences Inc. Receives its 9,000th E-Commerce Order CI
Tauriga Sciences Inc. Receives Product Endorsement from the State of Alaska CI
Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board CI
Tauriga Sciences, Inc. Appoints Matthew A. Shaw as Member of its Corporate Advisory Board CI
Tauriga Sciences, Inc. has Changed its Name to Sublingual Technologies Inc CI
Tauriga Sciences, Inc. Confirms the Commercial Launch of Its New & Improved Tauri-Gummies? Product, Kosher Certified by Orthodox Union CI
Tauriga Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Tauriga Sciences, Inc. to Proceed with the Production of Its Proprietary Kratom Infused Chewing Gum CI
Tauriga Sciences Inc. Enters into Strategic Alliance with Psychedelic Water CI
Tauriga Sciences Inc. Commences Development of Ashwagandha Infused Chewing Gum CI
Tauriga Sciences Inc. Expands its Product Offerings of Delta 8 THC Infused Gummies CI
Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum CI
Tauriga Sciences, Inc. Announces Resignation of David Wolitzky from the Board of Directors CI
More news
Managers TitleAgeSince
Chief Executive Officer 45 12-08-21
Director of Finance/CFO 55 17-07-04
Chief Tech/Sci/R&D Officer - 20-07-14
Members of the board TitleAgeSince
Director/Board Member 74 21-03-07
Chief Executive Officer 45 12-08-21
Director/Board Member 46 21-03-07
More insiders
Tauriga Sciences, Inc. is a science, technology and consumer products company. The Company operates through its subsidiary, Tauriga Pharma Corp., which is focused on the development of a pharmaceutical product line that is synergistic with the Company’s primary Cannabidiol (CBD) product line. The Company operates through two segments. The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. The second segment is the research and development division, which consists of liabilities and results from any activity relative to the progress in the development of the Company’s Food and Drug Administration (FDA) and Investigational New Drug (IND) application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. It also developed an immune booster version of Tauri-Gum chewing gum. This product contains 60 milligrams (mg) of Vitamin C and 10mg of Elemental Zinc per piece.
More about the company
  1. Stock
  2. Equities
  3. Stock Tauriga Sciences, Inc.
  4. Stock Tauriga Sciences, Inc. - Other OTC